Press Release January 08, 2018

Teva Announces $200 Million Global License Agreement With Alder BioPharmaceuticals®

The Life Sciences team advised Teva Pharmaceuticals International GmbH., a subsidiary of Teva Pharmaceutical Industries Ltd., on its global license agreement with Alder BioPharmaceuticals. The agreement validates Teva’s IP and resolves Alder’s opposition to Teva’s European Patent No. 1957106 B1, with respect to anti-calcitonin gene-related peptide (CGRP) antibodies and methods for their use.
 
Under the terms of the agreement, Alder has agreed to withdraw its appeal before the European Patent Office; make an immediate one-time payment of $25 million to Teva; make a second one-time payment of $25 million upon the approval of a biologics license application (BLA) for Alder’s eptinezumab; and, following the commercial launch of eptinezumab, pay $75 million at each of two sales-related milestones (at $1 billion and $2 billion in sales achieved in a calendar year); and provide certain royalty payments on net sales at rates from 5% to 7%.
 
Teva Pharmaceutical Industries Ltd. is a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions used by approximately 200 million patients in over 60 markets every day.
 
The Goodwin team was led by partner Robert Crawford with invaluable assistance from partners Elaine Blais and Christopher Holding.
 
For additional details on the agreement, please read the press release.